Episode 5: John Maraganore has been a champion of innovation throughout his career. He discusses the road to success at Alnylam, today's environment, and keeping the U.S. on top

Episode 6: BridgeBio Founder & CEO Neil Kumar discusses the hub and spoke biotech model and trying to build a sustainable business for the long-term

He and Matt talk about portfolio construction, and the dynamics of taking on the right capital structure throughout different phases of a company's lifecycle. Neil shares early learnings from the commercial launch of Attruby, how being a commercial stage company can impact culture, and why he created the early-stage R&D focused sister company Gondola. Plus, discussing talent, intellectual property, and more.

Episode 5: John Maraganore has been a champion of innovation throughout his career. He discusses the road to success at Alnylam, today's environment, and keeping the U.S. on top

Reflecting on the decades-long journey at Alnylam, John Maraganore describes making it through lean times, and how far oligos and RNAi have come today. Matt asks him about championing true innovation, and what the word 'innovation' even means in today's environment. Plus, his thoughts on China, drug pricing and access, IP, AI ,and more.

Episode 4: Matt speaks with Philip Ross, one of the most experienced and successful bankers in healthcare, about the M&A landscape and his decision to join Jefferies last year

Philip Ross talks about the outlook for M&A in our industry, and describes the pharma revenue growth demands that will be driving it. He discusses what qualities make targets attractive, and how the industry has changed over time during the course of his career. Plus, what attracted him to Jefferies.

Episode 3: Matt speaks with STAT News' Adam Feuerstein about the dynamics of biotech journalism and how it compares to other industries

Adam shares his background of previously covering the tech industry, and compares and contrasts it to covering biotech. He describes his philosophy of writing for investors, and how the business of journalism does and doesn't affect the types of stories he writes.

Episode 2: Matt speaks with Avoro Capital's Behzad Aghazadeh about the hot button issues that have been striking the biotech sector

One of the largest and most successful biotech investors, Dr. Aghazadeh is asked about key current events like turnover at FDA, tariffs, China, and whether he thinks biotech has a structural problem regarding how companies 'innovate' today and the different market strategies of investors.